In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

In a report released on April 2, Michael Cherny from Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), with a price ...

Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform. Analyst Price Forecast Suggests 419.11% Upside ...

Research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Maze Therapeutics in ...

Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings estimates for Immunic in a research note issued on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now expects that the ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...

Trump has repeatedly called April 2 “Liberation Day,” alluding to a more sweeping and aggressive set of tariffs. Leerink Partners analysts said that the risks from Trump’s tariffs on the biopharma ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to ...